Efficacy and safety of fixed doses of intranasal Esketamine as an add-on therapy to Oral antidepressants in Japanese patients with treatment-resistant depression: a phase 2b randomized clinical study

BACKGROUND: Esketamine nasal spray (Spravato) in conjunction with oral antidepressants (ADs) is approved in the European Union, United States, and other markets for treatment-resistant depression (TRD). Efficacy, safety, and tolerability of esketamine nasal spray in Japanese patients with TRD needs...

Descripción completa

Detalles Bibliográficos
Autores principales: Takahashi, Nagahide, Yamada, Aya, Shiraishi, Ayako, Shimizu, Hiroko, Goto, Ryosuke, Tominaga, Yushin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2021
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8547110/
https://www.ncbi.nlm.nih.gov/pubmed/34696742
http://dx.doi.org/10.1186/s12888-021-03538-y

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8547110/
https://www.ncbi.nlm.nih.gov/pubmed/34696742
http://dx.doi.org/10.1186/s12888-021-03538-y

Ejemplares similares